Beranda › Kanker Kolorektal › Illinois › Arlington Heights
Uji klinis Kanker Kolorektal di Arlington Heights, IL
12 studi untuk Kanker Kolorektal mencari peserta di lokasi sekitar Arlington Heights (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Family Communications After Genetic Testing
Menerima pesertaSukarelawan sehat diterima
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Menerima pesertaFase 3
- Alexian Brothers Medical Center, Elk Grove Village · 6 mi jauhnya
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Menerima pesertaFase 1
- Illinois Cancer Specialists, Arlington Heights
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Menerima pesertaFase 2
- Illinois Cancer Specialists, Arlington Heights
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Menerima pesertaStudi observasional
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Gastroenterology and Internal Medicine Specialists, Lake Barrington · 12 mi jauhnya
Uji klinis Kanker Kolorektal di kota lain
- Houston, TX102 studi
- New York City, NY78 studi
- Nashville, TN69 studi
- Boston, MA63 studi
- Los Angeles, CA59 studi
- Arlington, VA52 studi
- St. Louis, MO50 studi
- San Antonio, TX46 studi
- Philadelphia, PA44 studi
- Grand Rapids, MI40 studi
- Baldwin Park, CA37 studi
- Chicago, IL34 studi
Studi lain di Arlington Heights
- Kanker Paru Non-Sel Kecil12 studi
- Kanker Paru9 studi
- Kanker Payudara7 studi
- Gagal Jantung7 studi
- Kanker Metastatik6 studi
- Kolitis Ulseratif6 studi
- Kanker Kolon6 studi
- Kanker Ovarium5 studi
- Obesitas5 studi
- Kelebihan Berat Badan5 studi
- Kanker Prostat3 studi
- Kondisi Kulit3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.